Catheter Precision, Inc. filings document material events, operating results, shareholder votes, capital-structure matters, and governance disclosures for a NYSE American-listed company. The records include 8-K reports on financial results and business updates tied to the company’s electrophysiology products, including VIVO and LockeT, as well as strategic expansion activity.
VTAK’s proxy and current-report filings also cover stockholder approval matters, common-stock issuance proposals, convertible preferred stock series, promissory note amendments, royalty-right exchanges, related-party transaction disclosures, and other material agreements. These filings frame the company’s public reporting around medical device commercialization, financing arrangements, and corporate governance.
Catheter Precision, Inc. reported that its Chief Financial Officer, Philip J. Anderson, received a grant of stock options covering 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036.
The options were awarded as a compensation grant and vest 100% on the 180-day anniversary of the grant date. Following this grant, Anderson holds derivative securities representing rights to acquire 40,000 shares of Catheter Precision common stock through these options.
Catheter Precision, Inc. director Arno Andrew received a grant of stock options as part of his compensation. The award covers 40,000 options to buy common stock at an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 derivative securities of this type directly.
Catheter Precision, Inc. director James Joseph Caruso received a grant of options to buy 40,000 shares of common stock. The options have an exercise price of $1.15 per share and expire on March 26, 2036. According to the grant terms, the options vest 100% on the 180-day anniversary of the grant date.
Catheter Precision, Inc. director Martin J. Colombatto received a grant of stock options on Common Stock. The award covers 40,000 options with an exercise price of $1.15 per share, expiring on March 26, 2036. The options vest 100% on the 180-day anniversary of the grant date, and following this grant he holds 40,000 options directly.
Catheter Precision, Inc. is asking stockholders at an April 15, 2026 virtual special meeting to approve several financing-related proposals and a potential reverse stock split. Stockholders of record as of March 9, 2026, when 2,357,127 common shares were outstanding, may vote.
The company seeks approval under NYSE American rules for common shares issuable from new Series C, Series D and Series J preferred stock structures and a reduced conversion price on existing Series B preferred stock. These preferred series could, at specified floor prices and assuming full participation, convert into large numbers of common shares, including up to 252,047,623 shares from Series C, 31,508,572 from Series D and 6,083,005 from Series J, plus an increase in Series B conversion capacity from 335,214 to 1,252,344 shares.
Stockholders are also being asked to authorize a reverse stock split of common stock at a ratio between 1‑for‑2 and 1‑for‑100, at the board’s discretion within one year, primarily to help the company maintain NYSE American listing standards and potentially broaden institutional interest.
Catheter Precision, Inc. is asking stockholders to approve six proposals at a Special Meeting on April 15, 2026, primarily to authorize multiple preferred‑stock issuances and related conversions and to permit a board‑determined reverse stock split.
The company seeks approval to issue Series C, Series D, Series J and reduced‑price Series B convertible preferred stock that, if converted at stated floors or terms, could add up to 252,047,623 (Series C), 31,508,572 (Series D), 6,083,005 (Series J) and 1,252,344 (Series B) shares of Common Stock. Shares outstanding were 2,357,127 as of the record date (March 9, 2026).
The board also asks authority to effect a reverse stock split at a ratio between 1‑for‑2 and 1‑for‑100, to be chosen by the board if approved. Record date and registration/filing mechanics are described in the proxy materials.
Catheter Precision, Inc. is raising capital through a private placement of preferred stock and using part of the funds to buy aviation-related assets. The company agreed to sell 1,853 shares of Series C-1 Convertible Preferred Stock for $1,853,000, initially convertible into up to 1,295,805 common shares at $1.43 per share, with future conversion prices tied to trading levels and subject to a floor that the company may waive. Investors also committed to buy additional Series C-2 and C-3 preferred shares for $1,853,000 each, and may later purchase up to $35,559,326 of Series C-4 Preferred Stock, all with variable conversion prices based on 80% of market measures and floor-price conditions. The company plans to use net proceeds for working capital, restructuring its legacy catheter business, settling legacy liabilities, simplifying its capital structure, and cutting operating expenses.
In a linked transaction, Catheter Precision agreed to acquire 80.02% of Fly Flyte, Inc. and all membership interests of Ponderosa Air, LLC from Creatd, Inc. for total consideration of $11,554,827, consisting of $776,827 cash at closing, a $5,000,000 zero‑coupon note due by December 15, 2026, and 5,778 shares of Series D Convertible Preferred Stock with an aggregate stated value of $5,778,000. Issuance and conversion of multiple preferred series depend on stockholder approval under NYSE American Section 713 and effectiveness of SEC resale registration statements. The company also amended its preferred stock designations to increase authorized Series C‑1 shares and granted registration rights for resale of common shares underlying the preferred stock.
Catheter Precision, Inc. chairman and CEO David A. Jenkins reported two Form 4 transactions involving Series J Preferred Stock. The Series J shares were issued under an exchange agreement that cancels an accrued royalty amount and terminates a royalty right in return for this preferred stock, as described in a related Form 8-K. Jenkins holds 2,491.293 Series J shares directly and 6,998.195 Series J shares indirectly through FatBoy Capital LP, whose general partner is SeaCap Management LLC, where he is managing member. The Series J Preferred Stock is not exercisable until stockholder approval is received and it has no expiration date.
Catheter Precision, Inc. reported that a group of investment funds and related managers collectively hold a significant passive stake in its common stock. The largest reported holder, Jonathan Juchno, beneficially owns 205,591 shares, representing 9.6% of the outstanding common stock. Other reporting persons include C/M Capital Master Fund, WVP Emerging Manager Onshore Fund, C/M Capital Partners, Mercer Street Global Opportunity Fund, Mercer Street Capital Partners, and Thomas Walsh, with individual stakes ranging from 2.6% to 6.4%. The ownership percentages are based on 2,131,563 shares of common stock outstanding as of the reference date. The filers certify that the securities were acquired and are held without the purpose or effect of changing or influencing control of Catheter Precision.
Catheter Precision, Inc. entered into Series J Exchange Agreements to swap accrued royalty rights with CEO David Jenkins and FatBoy Capital, LP into 9,489.488 shares of new Series J Convertible Preferred Stock, representing royalty amounts with a net present value of $9,489,487.81 as of December 31, 2025.
The Series J Preferred Stock has a stated value of $1,000 per share and is convertible into common stock at a fixed price of $1.56 per share, matching the December 31, 2025 closing price. These preferred shares are collectively convertible into 6,083,005 common shares, or about 641 common shares per preferred share, if and only if stockholder approval is obtained under NYSE American rules.
The royalty rights and accrued royalty amounts are terminated as of December 31, 2025, removing this obligation. Separately, the company highlighted a strategic institutional financing for up to $36.5 million and the agreed termination of its at-the-market equity offering program, describing these steps as strengthening its balance sheet and aligning long-term institutional capital.